ClinicalTrials.gg
CompletedNCT02736721Updated Sep 20, 2016Results posted

Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)

A Phase 3 interventional study of Peginterferon alfa-2a in Myelogenous Leukemia, Chronic, sponsored by Hoffmann-La Roche. Completed at 5 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-20.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Germany — 10 open to participants now, 16 under way, 3 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany.

Enrollment
60th of 77
41 · median 171
Started
2003
the only one that year
Phase 3
25 of 90
1 open now
Registered
66th of 90
by date

Among the 90 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Germany, this one is the 60th largest by enrollment of the 77 interventional ones that give a count, is the only one that started in 2003, is one of 25 in phase 3, and was the 66th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

10 of the 90 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Germany are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Germany, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety and tolerability of long-term use of peginterferon alfa-2a in participants with CML who have previously participated in peginterferon alfa-2a study ML16544 (NCT number not available), NO16006 (NCT number not available) or ML17228 (NCT number not available) and treating physician has decided to continue treatment with peginterferon alfa-2a within the frame of another clinical study.

03

Conditions studied

  • Myelogenous Leukemia, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with CML
  • Previous participation in studies: ML16544, NO16006 or ML17228; for which the treating physician recommends a continuation of the study drug according to defined minimal criteria

Exclusion criteria

Exclusion Criteria:

  • Major protocol violator in the participated study prior to participation in this study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Peginterferon alfa-2a

    Participants will receive peginterferon alfa-2a subcutaneously in doses between 90 and 450 microgram (mcg) once weekly until medically indicated as judged by the treating investigator.

    Drug: Peginterferon alfa-2a

Interventions

  • Peginterferon alfa-2a in doses between 90 and 450 mcg will be administered subcutaneously once weekly until medically indicated as judged by the treating investigator.

    Also known as: Pegasys

06

What researchers measure

Primary outcomes

  1. Number of Participants With Complete Hematologic Response

    Hematologic response was considered to be achieved if participants met all of the following criteria: normalization of white blood cells count to less than (\<) 10\*10\^9 per liter (/L) with normal differentiation, normalization of platelet count at \<450\*10\^9/L, and disappearance of all signs and symptoms of the disease. This response had to be confirmed at least 4 weeks after the first measure and beyond that.

    Time frame: Up to approximately 7 years

  2. Time to Loss of Previous Hematologic Response

    Time to loss of previous hematologic response was defined as the interval between the first day of treatment in the study and the first day of loss of previous hematologic response during elapsed time of study. Hematologic response was considered to be achieved if participants met all of the following criteria: normalization of white blood cells count to \<10\*10\^9/L with normal differentiation, normalization of platelet count at \<450\*10\^9/L, and disappearance of all signs and symptoms of the disease. This response had to be confirmed at least 4 weeks after the first measure and beyond that.

    Time frame: Up to approximately 7 years

  3. Number of Participants With Major Cytogenetic Response (CyR)

    CyR was based on the prevalence of Philadelphia chromosome-positive (Ph+) bone marrow cells in metaphase determined from reverse transcriptase polymerase chain reaction (RT-PCR). Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was absence of detectable Ph+ bone marrow cells and PCyR was achieved when 1 to 34 percent (%) of bone marrow cells were Ph+.

    Time frame: Up to approximately 7 years

  4. Time to Loss of Previous CyR

    Time to loss of previous CyR was defined as the interval between the first day of treatment in the study and the first day of loss of previous CyR. CyR is based on the prevalence of Ph+ bone marrow cells in metaphase. Major CyR was categorized as either CCyR or PCyR. CCyR was achieved when there was absence of detectable Ph+ bone marrow cells and PCyR was achieved when 1 to 34% of bone marrow cells were Ph+.

    Time frame: Up to approximately 7 years

  5. Number of Participants With Molecular Response (MR)

    MR was assessed using breakpoint cluster region - Abelson (BCR-ABL) proto-oncogene transcript levels measured by RT-PCR from peripheral blood. Number of participants with BCR-ABL/ABL ratio less than or equal to 10 (%) was reported.

    Time frame: Up to approximately 7 years

  6. Time to Loss of Previous MR

    Time to loss of previous MR was defined as the interval between the first day of treatment in the study and the first day of loss of previous MR. MR was assessed using BCR-ABL transcript levels measured by RT-PCR from peripheral blood.

    Time frame: Up to approximately 7 years

07

Results

Posted Aug 5, 2016

Participant flow

Participant flow — Overall Study
MilestonePeginterferon Alfa-2a
Started41
Completed25
Not completed16
Withdrew: Adverse event8
Withdrew: Lost to follow-up3
Withdrew: Other5

Outcome measures

PrimaryNumber of Participants With Complete Hematologic Response

Hematologic response was considered to be achieved if participants met all of the following criteria: normalization of white blood cells count to less than (\<) 10\*10\^9 per liter (/L) with normal differentiation, normalization of platelet count at \<450\*10\^9/L, and disappearance of all signs and symptoms of the disease. This response had to be confirmed at least 4 weeks after the first measure and beyond that.

Time frame:
Up to approximately 7 years
Reported as:
Number · participants
Number of Participants With Complete Hematologic Response
participantsPeginterferon Alfa-2a
Number of Participants With Complete Hematologic Response40
PrimaryTime to Loss of Previous Hematologic Response

Time to loss of previous hematologic response was defined as the interval between the first day of treatment in the study and the first day of loss of previous hematologic response during elapsed time of study. Hematologic response was considered to be achieved if participants met all of the following criteria: normalization of white blood cells count to \<10\*10\^9/L with normal differentiation, normalization of platelet count at \<450\*10\^9/L, and disappearance of all signs and symptoms of the disease. This response had to be confirmed at least 4 weeks after the first measure and beyond that.

Time frame:
Up to approximately 7 years
Reported as:
Median · months
Time to Loss of Previous Hematologic Response
monthsPeginterferon Alfa-2a
Time to Loss of Previous Hematologic ResponseNA (NA to NA)
PrimaryNumber of Participants With Major Cytogenetic Response (CyR)

CyR was based on the prevalence of Philadelphia chromosome-positive (Ph+) bone marrow cells in metaphase determined from reverse transcriptase polymerase chain reaction (RT-PCR). Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was absence of detectable Ph+ bone marrow cells and PCyR was achieved when 1 to 34 percent (%) of bone marrow cells were Ph+.

Time frame:
Up to approximately 7 years
Reported as:
Number · participants
Number of Participants With Major Cytogenetic Response (CyR)
participantsPeginterferon Alfa-2a
Number of Participants With Major Cytogenetic Response (CyR)40
PrimaryTime to Loss of Previous CyR

Time to loss of previous CyR was defined as the interval between the first day of treatment in the study and the first day of loss of previous CyR. CyR is based on the prevalence of Ph+ bone marrow cells in metaphase. Major CyR was categorized as either CCyR or PCyR. CCyR was achieved when there was absence of detectable Ph+ bone marrow cells and PCyR was achieved when 1 to 34% of bone marrow cells were Ph+.

Time frame:
Up to approximately 7 years
Reported as:
Median · years
Time to Loss of Previous CyR
yearsPeginterferon Alfa-2a
Time to Loss of Previous CyRNA (NA to NA)
PrimaryNumber of Participants With Molecular Response (MR)

MR was assessed using breakpoint cluster region - Abelson (BCR-ABL) proto-oncogene transcript levels measured by RT-PCR from peripheral blood. Number of participants with BCR-ABL/ABL ratio less than or equal to 10 (%) was reported.

Time frame:
Up to approximately 7 years
Reported as:
Number · participants
Number of Participants With Molecular Response (MR)
participantsPeginterferon Alfa-2a
Number of Participants With Molecular Response (MR)38
PrimaryTime to Loss of Previous MR

Time to loss of previous MR was defined as the interval between the first day of treatment in the study and the first day of loss of previous MR. MR was assessed using BCR-ABL transcript levels measured by RT-PCR from peripheral blood.

Time frame:
Up to approximately 7 years
Reported as:
Median · years
Time to Loss of Previous MR
yearsPeginterferon Alfa-2a
Time to Loss of Previous MRNA (NA to NA)

Adverse events

Collected over Up to approximately 7 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peginterferon Alfa-2a—13/41 (31.7%)35/41 (85.4%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPeginterferon Alfa-2a
General physical health deteriorationGeneral disorders2/41
CholelithiasisHepatobiliary disorders2/41
Atrial fibrillationCardiac disorders1/41
Intestinal haemorrhageGastrointestinal disorders1/41
CholecystitisHepatobiliary disorders1/41
AppendicitisInfections and infestations1/41
CellulitisInfections and infestations1/41
GastroenteritisInfections and infestations1/41
InfectionInfections and infestations1/41
PneumoniaInfections and infestations1/41
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPeginterferon Alfa-2a
ArthralgiaMusculoskeletal and connective tissue disorders7/41
DepressionPsychiatric disorders7/41
FatigueGeneral disorders5/41
Influenza like illnessGeneral disorders5/41
BronchitisInfections and infestations5/41
NasopharyngitisInfections and infestations5/41
Back painMusculoskeletal and connective tissue disorders5/41
Muscle spasmsMusculoskeletal and connective tissue disorders5/41
ErythemaSkin and subcutaneous tissue disorders5/41
NeutropeniaBlood and lymphatic system disorders4/41

Baseline characteristics

Analysis population included all enrolled participants.

Age, Continuous
Age, Continuous(years)Peginterferon Alfa-2a
Mean48.5 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Peginterferon Alfa-2a
Female14
Male27
08

Study locations

5 sites
  • Freiburg, 79106, Germany
  • Mainz, 55101, Germany
  • Mannheim, 68167, Germany
  • Marburg, 35043, Germany
  • Tübingen, 72076, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 5 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2016
First posted
Apr 13, 2016
Start
Sep 2003
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Aug 5, 2016
Last update
Sep 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02736721
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 13, 2016
Start date
Sep 2003
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Aug 5, 2016
Last update
Sep 20, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion